Government Paying Closer Focus On Cleveland BioLabs, Inc (NASDAQ:CBLI)’s Radiation Countermeasure, Sources Say

Cleveland BioLabs, Inc (NASDAQ:CBLI), which happens to be one of the top biopharmaceutical providers prides itself in having one of the best applications in radiation mitigation, vaccines and the oncology immunotherapy products which help patients globally in a huge way towards facing out the conditions they have been struggling with over the years.

According to sources, the top company is said be performing quite well in terms of business but the most eye-catching attribute lies in the fact that its Entolimod Biodefense currently shows up as the most advanced as well as the most dependable Protectan product candidate.

The great news and that is line with what will benefit patients globally in a significant way is the fact that it is being developed as a radiation countermeasure and is as a matter of fact expected to go a long way towards preventing the deaths that usually occur as a result of the Acute Radiation Syndrom (ARS).

One of the most outstanding news developments about the industry is the fact that the market for radiation has witnessed major expansions and that has primarily been attributed to the perceived threat of biological, chemical, radiation as well as nuclear attacks.

Asides from having the government of the United States which happens to maintain a national stockpile of emergency products, other potential customers include state and local governments, NGOs, foreign governments, security companies, multinational corporations, healthcare providers as well as the nuclear power facilities.

From some other sources, the news just trickling in have indicated the action by FDA in moving ahead to authorize the provider to initiate an in vivo biocomparability research to look into the various entolimod formulations in non-human primates.

As you would have guessed it, the study seeks out to try and compare the historical drug formulation that was utilized in some prior studies to the to-be-marketed drug formulation of entolimod handed in for the pre-Emergency Use Authorization (pre-EUA).

As a matter of fact, if indeed the FDA moves ahead to actually give approval to the pre-EUA application, that will then mean that the federal government agencies will have the go-ahead to procure entolimod for stockpiling and that will be great since it will be possible to distribute the drug effectively during the instances of emergency.

For consideration of being featured on WallstreetPR, contact:

Please make sure to read and completely understand our disclaimer at FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any content posted on our website is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. WallStreetPR strongly recommends you consult a licensed or registered professional before making any investment decision. Neither nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. WallStreetPR often gets compensated for advertisement services that are disclosed on our disclaimer located at

Published by Benjamin Roussey

Benjamin Roussey is from Sacramento, California. He has two master’s degrees and served four years in the U.S. Navy. His bachelor’s degree is from CSUS (1999) where he was on a baseball pitching scholarship. His second master’s degree is an MBA in Global Management from the University of Phoenix (2006). He has worked for small businesses, public agencies, and large corporations. He has lived in Korea and Saudi Arabia where he was an ESL instructor. Benjamin spends his time in between Northern California and Cabo San Lucas, Mexico, committing himself to his craft of freelance and website writing.